0|chunk|Systems Analysis of a RIG-I Agonist Inducing Broad Spectrum Inhibition of Virus Infectivity
0	28	35 Agonist	Chemical	CHEBI_48705

1|chunk|The RIG-I like receptor pathway is stimulated during RNA virus infection by interaction between cytosolic RIG-I and viral RNA structures that contain short hairpin dsRNA and 59 triphosphate (59ppp) terminal structure. In the present study, an RNA agonist of RIG-I was synthesized in vitro and shown to stimulate RIG-I-dependent antiviral responses at concentrations in the picomolar range. In human lung epithelial A549 cells, 59pppRNA specifically stimulated multiple parameters of the innate antiviral response, including IRF3, IRF7 and STAT1 activation, and induction of inflammatory and interferon stimulated genes -hallmarks of a fully functional antiviral response. Evaluation of the magnitude and duration of gene expression by transcriptional profiling identified a robust, sustained and diversified antiviral and inflammatory response characterized by enhanced pathogen recognition and interferon (IFN) signaling. Bioinformatics analysis further identified a transcriptional signature uniquely induced by 59pppRNA, and not by IFNa-2b, that included a constellation of IRF7 and NF-kB target genes capable of mobilizing multiple arms of the innate and adaptive immune response. Treatment of primary PBMCs or lung epithelial A549 cells with 59pppRNA provided significant protection against a spectrum of RNA and DNA viruses. In C57Bl/6 mice, intravenous administration of 59pppRNA protected animals from a lethal challenge with H1N1 Influenza, reduced virus titers in mouse lungs and protected animals from virus-induced pneumonia. Strikingly, the RIG-I-specific transcriptional response afforded partial protection from influenza challenge, even in the absence of type I interferon signaling. This systems approach provides transcriptional, biochemical, and in vivo analysis of the antiviral efficacy of 59pppRNA and highlights the therapeutic potential associated with the use of RIG-I agonists as broad spectrum antiviral agents.
1	24	31 pathway	Chemical	CHEBI_34922
1	53	56 RNA	Chemical	CHEBI_33697
1	122	125 RNA	Chemical	CHEBI_33697
1	164	169 dsRNA	Chemical	CHEBI_67208
1	177	189 triphosphate	Chemical	CHEBI_18036
1	243	246 RNA	Chemical	CHEBI_33697
1	247	254 agonist	Chemical	CHEBI_48705
1	328	337 antiviral	Chemical	CHEBI_22587
1	494	503 antiviral	Chemical	CHEBI_22587
1	591	601 interferon	Chemical	CHEBI_52999
1	652	661 antiviral	Chemical	CHEBI_22587
1	808	817 antiviral	Chemical	CHEBI_22587
1	895	905 interferon	Chemical	CHEBI_52999
1	1310	1313 RNA	Chemical	CHEBI_33697
1	1318	1321 DNA	Chemical	CHEBI_16991
1	1678	1688 interferon	Chemical	CHEBI_52999
1	1789	1798 antiviral	Chemical	CHEBI_22587
1	1894	1902 agonists	Chemical	CHEBI_48705
1	1921	1930 antiviral	Chemical	CHEBI_22587
1	CHEBI-CHEBI	CHEBI_34922	CHEBI_33697
1	CHEBI-CHEBI	CHEBI_34922	CHEBI_67208
1	CHEBI-CHEBI	CHEBI_34922	CHEBI_18036
1	CHEBI-CHEBI	CHEBI_34922	CHEBI_48705
1	CHEBI-CHEBI	CHEBI_34922	CHEBI_22587
1	CHEBI-CHEBI	CHEBI_34922	CHEBI_52999
1	CHEBI-CHEBI	CHEBI_34922	CHEBI_16991
1	CHEBI-CHEBI	CHEBI_33697	CHEBI_67208
1	CHEBI-CHEBI	CHEBI_33697	CHEBI_18036
1	CHEBI-CHEBI	CHEBI_33697	CHEBI_48705
1	CHEBI-CHEBI	CHEBI_33697	CHEBI_22587
1	CHEBI-CHEBI	CHEBI_33697	CHEBI_52999
1	CHEBI-CHEBI	CHEBI_33697	CHEBI_16991
1	CHEBI-CHEBI	CHEBI_67208	CHEBI_18036
1	CHEBI-CHEBI	CHEBI_67208	CHEBI_48705
1	CHEBI-CHEBI	CHEBI_67208	CHEBI_22587
1	CHEBI-CHEBI	CHEBI_67208	CHEBI_52999
1	CHEBI-CHEBI	CHEBI_67208	CHEBI_16991
1	CHEBI-CHEBI	CHEBI_18036	CHEBI_48705
1	CHEBI-CHEBI	CHEBI_18036	CHEBI_22587
1	CHEBI-CHEBI	CHEBI_18036	CHEBI_52999
1	CHEBI-CHEBI	CHEBI_18036	CHEBI_16991
1	CHEBI-CHEBI	CHEBI_48705	CHEBI_22587
1	CHEBI-CHEBI	CHEBI_48705	CHEBI_52999
1	CHEBI-CHEBI	CHEBI_48705	CHEBI_16991
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_52999
1	CHEBI-CHEBI	CHEBI_22587	CHEBI_16991
1	CHEBI-CHEBI	CHEBI_52999	CHEBI_16991

